Rep. Ed Markey (D-MA) introduced the Trial and Experimental Studies Transparency (TEST) Act into congress on August 2, 2012; a bill aimed at closing loopholes in the current FDA process for trial registration. The New England Journal of Medicine, in an editorial penned by Dr. Jeffrey M. Drazen, says “… clinical trials should be conducted in the open, with full public knowledge of the question asked, the intervention tested, and the results obtained. The TEST Act is another step toward this end, and we strongly support it.”
